For the week, the Dow Jones Industrial Average gained over 1,200 points to 25,538 while the S&P 500 rose 4.8% to 2,760. The Nasdaq Composite jumped the highest on a percentage basis for the week as Tech stocks caught a bit of relief. It rose over 5.6% to 7,330.
In ETFs, Emerging markets and Treasuries saw some of the greatest inflows in the month of November, according to our ETFG Fund Flow summary. One of the ETFs that took in the biggest flows was IEMG, the iShares Core MSCI Emerging Market ETF. In the month of November, IEMG took in over $3.24B or about 8% of its AUM. SHY, which is iShares 1-3 year Treasury Bond ETF, has followed suit with inflows of over $1.8B, or about 17% of its AUM.
In the ETFG Quant Movers, we saw sector based ETPs gain the most percentage points to their overall scores. The Invesco Dynamic Pharmaceutical ETF (PJP) and iShares Global Telecom ETF (IXP) added 11.15% and 11.00% to their overall Quant scores respectively.
In the loser’s column, we saw emerging markets ETPs dropping some percentage points to their overall score. The iShares MSCI Emerging Markets Asia ETF (EEMA), Invesco Emerging Markets Infrastructure ETF (PXR) and the iShares Edge MSCI Min Vol Emerging Markets ETF (EEMV)lost 10.63%, 9.59% and 9.24% to their overall scores respectively.
ETFG Weekly Select List - the 5 most highly rated ETFs per Sector, Geographic Region and Strategy as ranked by the ETFG Quant model.
Because of the sector’s success in the major indexes this week, we’d like to highlight some substantial movement in the Global portion when comparing this week’s Select List to last. The iShares Global Healthcare ETF (IXJ) jumped up two spots to be the top ranked fund in the sector. It took over for the iShares Global Consumer Staples ETF (KXI) which is now in the 3rd ranked spot. The iShares Global 100 ETF (IOO) held steady at the 2nd spot for two consecutive weeks while the VanEck Vectors Biotech ETF (BBH) moved into the 5th spot knocking the Invesco Shipping ETF (SEA) off the list.
Thanks for reading ETF Global Perspectives
ETFG 21 Day Free Trial:
Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. ETF Global LLC (“ETFG”) and its affiliates and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively ETFG Parties) do not guarantee the accuracy, completeness, adequacy or timeliness of any information, including ratings and rankings and are not responsible for errors and omissions or for the results obtained from the use of such information and ETFG Parties shall have no liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of such information. ETFG PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall ETFG Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of the information contained in this document even if advised of the possibility of such damages.
ETFG ratings and rankings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities or to make any investment decisions. ETFG ratings and rankings should not be relied on when making any investment or other business decision. ETFG’s opinions and analyses do not address the suitability of any security. ETFG does not act as a fiduciary or an investment advisor. While ETFG has obtained information from sources they believe to be reliable, ETFG does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor.